Recurrent Splenic Marginal Zone Lymphoma: Clinical Trials

2 trials for Recurrent Splenic Marginal Zone Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 not yet recruiting. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Not yet recruiting 1

Follow Recurrent Splenic Marginal Zone Lymphoma: new trials by email Literature Review of Recurrent Splenic Marginal Zone Lymphoma trials Research Report on Recurrent Splenic Marginal Zone Lymphoma

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma
Phase 2Not yet recruitingSWOG Cancer Research Network1382026-10-032026-10-13
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Phase 2CompletedMayo Clinic652015-02-192026-06-24

Narrower conditions

Lymphoma, B-Cell, Marginal Zone (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Follicular (1)  ·  Waldenstrom Macroglobulinemia (1)

Broader conditions

Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoma (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Blood Protein Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Hematologic Diseases (1)  ·  Hemorrhagic Disorders (1)

Interventions

Biopsy (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Specimen Handling (1)  ·  ibrutinib (1)  ·  idelalisib (1)  ·  pembrolizumab (1)  ·  polatuzumab vedotin (1)  ·  zanubrutinib (1)

Sponsors

Mayo Clinic (1)  ·  SWOG Cancer Research Network (1)

Countries

United States (2)

Top investigators

Boyu Hu (1)  ·  Wei Ding (1)

Results publications

PMID 28424162

NIH funding

P50CA097274 (1), U10CA180888 (1)